Approved Excipients
SeraNovo’s proprietary technology platform provides you with the option of a liquid formulation, a solid formulation (also called a “Glass”) or both. The Glass formulations are dehydrated eutectic mixtures, liquefying upon contact with water. This provides enhanced stability as well as a high drug load while keeping the production costs low in relation to conventional solid formulation production costs (e.g. spray drying). The table below highlights the various advantages compared to a conventional formulation technology, the Amorphous Solid Dispersion. The figure shows a schematic representation of what two finished DES dosages forms could look like.

| Physical Stability | Production Cost | Capability | API availability | DES company | Stability
|--------------------|-----------------|------------|-----------------|-------------|---------|
| Amorphous Solid Dispersion | $1.00/mg per 1000 gram | High | Limited | Usually applicable | Exceeds 2 years
| Deep Solid Eutectic Solvent | $0.50/mg for 1 Literature & 1 Commercial | Low | High | Usually applicable | Exceeds 2 years
| Finished dosage form | | | | | |

Frequently Asked Questions:
1. What are the major benefits of SeraNovo’s technology compared to competing technology?
2. What about bioavailability enhancement compared to leading techniques such as spray drying and cheaper production.
3. What is the regulatory framework around these “new solvents”? Does each new solvent have to be registered as a new excipient?
4. The solvent breaks up in contact with water, leaving a solution of the individual excipients which are already accepted by the FDA, no additional registration required.
5. How do you scale up the formulations?
6. SeraNovo has designed its technology to be easily scalable, for example for a liquid formulation the machine used is available in sizes ranging from 3 litres to 100-300 litres.
7. Can the Glass formulations be pressed into tablets?
8. No, however capsules are recommended for early studies for dose variability and time saving.
9. Does SeraNovo have in-house technology?
10. No, SeraNovo is the sole owner of several patents in various stages of application.
11. What development timelines are expected?
12. Treated for feasibility studies are 2-3 months and 3-6 months for formulation development. Timelines may vary depending on stability studies and any specific customer requirements.

Contact: info@seranovo.com